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Abbreviations 
 
CHO:  Chinese hamster ovary 
DMSO:  dimethyl sulfoxide 
GAPDH : glyceraldehyde-3-phosphate dehydrogenase 
HEK:  human embryonic kidney 
PBS:  phosphate-buffered saline 
PCR:  polymerase chain reaction 
VEGF:  vascular endothelial growth factor 
CXCR:  CXC chemokine receptor 
SDF1:  stromal cell-derived factor 1 
VEGFR: vascular endothelial growth factor receptor 
CD44:  cluster of designation or classification determinant 44 
LYVE-1: lymphatic vessel endothelial hyaluronan receptor-1 
HAT:  hypoxanthine-aminopterin-thymidine 
HRP:  horseradish peroxidase 
FBS:  fetal bovine serum 
HBSS:  Hank's Balanced Salt Solution 
MAb:  monoclonal antibody 
ELISA:  enzyme-linked immuno-sorbent assay 
O.C.T:  optimal cutting temperature 
IHC:  immunohistochemistry 
CXCL:  C-X-C motif ligand 
cAMP:  cyclic adenosine 3′,5′-monophosphate 
IBMX:  3-Isobutyl-1-methylanxthine 
MMPs:  matrix metalloproteinase 
HGF:  hepatocyte growth factor 
EMT:  epithelial-mesenchymal transition 
HER2:  human epidermal growth factor receptor 2 
cDNA:  complementary deoxyribonucleic acid 
IgG:  Immunoglobulin G 
Ig:  Immunoglobulin 
SCID mice: C.B-17/Icr-scid Jcl 
FFPE:  formalin-fixed paraffin-embedded 
DAB:  3,3′-diaminobenzidine 
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mRNA:  messenger ribonucleic asid 
siRNA:  small interfering ribonucleic asid 
CD31:  cluster of designation or classification determinant 31 
HMVEC-Lly: Human lung lymphatic microvascular endothelial cells 
FACS:  fluorescence activated cell sorting 
FRET:  Fluorescence resonance energy transfer 
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Abstract 
Cancer is the most common cause of death in Japan since 1981. Cancer death is deeply 
associated with tumor metastasis. The lethality of patients with metastatic diseases is 
much higher than that of patients with localized tumors. Therefore, therapeutic modalities 
capable of inhibiting tumor metastasis would be beneficial for the treatment of many 
tumors. However, to date, no anti-metastatic drug is available. The objectives of this study 
were to generate novel drug candidates that have antitumor metastatic activity. 
In Chapter I, the author developed an anti-VEGF-D monoclonal antibody, cVE199, 
and investigated its in vitro properties, in vivo effects against tumors, and possible target 
indications. VEGF-D has been implicated in the promotion of the metastatic potential of 
several tumors. The cVE199 molecule specifically bound to human VEGF-D. In addition, 
cVE199 inhibited the biological activity of VEGF-D/VEGFR-3 signal transduction in 
vitro. Because the author determined that a neuroblastoma cell line, SK-N-DZ, 
abundantly expressed VEGF-D, an in vivo efficacy study was performed using a SK-N-
DZ xenograft model. cVE199 significantly decreased SK-N-DZ lymphatic metastasis. 
Finally, the author investigated VEGF-D expression in human neuroblastoma and 
determined that the molecule was expressed in 11 out of 29 human neuroblastoma 
specimens (37.9%). In conclusion, in Chapter I, the author found that a novel anti-VEGF-
D monoclonal antibody, cVE199, with specific reactivity against human VEGF-D, 
prevents lymphatic metastasis of neuroblastoma in an animal model. In addition, my 
results show that VEGF-D is expressed in some cases of human neuroblastoma, which 
suggests that cVE199 is a potential anti-metastatic therapeutic antibody for 
neuroblastoma treatment. 
In Chapter II, the author developed a novel anti-CXCR4 monoclonal antibody, CF172, 
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and investigated its anti-metastatic activity against rhabdomyosarcoma cells. CXCR4 has 
been implicated in the promotion of the metastatic potential of rhabdomyosarcoma. The 
CF172 molecule specifically bound to human CXCR4 and neutralized CXCR4/SDF1 
signal transduction. Using CF172, the author determined that the rhabdomyosarcoma cell 
line, SJCRH30, expressed high levels of CXCR4. In addition, CF172 inhibited the SDF1-
induced migration activity of SJCRH30 cells in vitro. Using SJCRH30 xenograft models, 
the author performed in vivo efficacy studies for peritoneal and lymph node metastasis, 
which are clinically observed in rhabdomyosarcoma. These studies indicated that CF172 
significantly decreased both types of metastasis. In conclusion, in Chapter II, the author 
found that a novel anti-CXCR4 monoclonal antibody, CF172, with specific reactivity 
against human CXCR4, prevented peritoneal metastasis and lymph node metastasis of 
rhabdomyosarcoma in animal models. These results suggest that CF172 is a potential 
anti-metastatic therapeutic antibody for rhabdomyosarcoma treatment. 
In conclusion, the author identified two monoclonal antibodies, cVE199 and CF172, 
which specifically target VEGF-D and CXCR4, respectively. Both antibodies presented 
antitumor metastasis activities in animal models. These data suggest that these antibodies 
are promising anti-metastatic therapeutics for cancer treatment. 
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General Introduction 
Cancer is a disease, which involves abnormal cell growth with the potential to invade or 
spread to other parts of the body (Dudjak 1992). Cancer is the most common cause of 
death in Japan since 1981. Molecular targeted therapy (e.g., anti-HER2 antibody: 
trastuzumab) improved treatment results for some tumor types. However, these 
improvements are still limited (Allemani et al. 2015). Therefore, it is still important to 
generate novel antitumor drugs. 
Metastasis is of great importance for the clinical management of cancer since cancer 
mortality is mainly associated with disseminated disease rather than with the primary 
tumor (Fidler 1999). Therefore, therapeutic modalities capable of inhibiting tumor 
metastasis would be beneficial for the treatment of many tumors. However, to date, no 
anti-metastatic drug is available. In fact, metastasis is an extraordinarily complex process. 
To successfully colonize a secondary site, a cancer cell must complete a sequential series 
of steps before it becomes a clinically detectable lesion. The details of the mechanisms of 
tumor metastasis are as follows: (a) proliferation of tumors within the primary site, (b) 
detachment from the primary site and invasion into the blood/lymphatic vessels, (c) 
chemotaxis in the vessels, and (d) provide a favorable microenvironment for tumor cell 
survival and growth (Fidler and Ellis 2000, Fidler 2002, Yeung et al. 2015).  
Based on these information, the author focused on the lymphatic vessels (categorized 
in step (b)) and chemotaxis (categorized in step (c)) to generate novel anti-metastatic 
drugs. Lymphatic metastasis, defined by the invasion of the lymph nodes by cancer cells, 
is known as the first step of metastasis in most cancers. Lymphatic vessels are important 
factors for lymphatic metastasis because most vessels that directly connect to lymph 
nodes are lymphatic vessels (Stacker et al. 2014). Indeed, there is a positive correlation 
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between tumor lymphatic vessel density and lymphatic metastasis (Frech et al. 2009, 
Chung et al. 2010). Therefore, the author attempted to generate an anti-lymphangiogenic 
antibody as an anti-metastatic drug. A novel member of the vascular endothelial growth 
factor (VEGF) family, namely VEGF-D, has been implicated in the promotion of 
lymphangiogenesis. In general, VEGF-D binds to the VEGF receptor (VEGFR)-2, found 
on both the blood and lymphatic vessels, and VEGFR-3, found predominantly on the 
lymphatic vessels and in some angiogenic tumor blood vessels (Achen et al. 1998, 
Saharinen et al. 2004). VEGFR-3 signaling is the primary factor responsible for the 
lymphangiogenic response to VEGF-D stimulation and leads to lymphangiogenesis in 
mouse models (Veikkola et al. 2001). Several experimental and clinical studies indicated 
positive correlations between VEGF-D expression, tumor lymphatic vessel density, and 
lymphatic metastasis (Achen and Stacker 2008). Moreover, a number of reports showed 
that higher VEGF-D expression correlates with poor prognosis in human tumors (White 
et al. 2002, Nakamura et al. 2003, Yokoyama et al. 2003, Juttner et al. 2006, Liu et al. 
2008). Therefore, VEGF-D blockade seems to be a promising method to prevent 
lymphatic metastasis of tumors.  
Regarding chemotaxis during tumor metastasis, chemokines, small pro-inflammatory 
chemoattractant proteins that bind to G-protein coupled receptors present on the cell 
surfaces of target cells, are major regulators of cell trafficking (Bockhorn et al. 2007). 
The chemokine, stromal cell-derived factor 1 (SDF1), and its receptor, CXC chemokine 
receptor-4 (CXCR4), play a unique role in homing and migration of hematopoietic and 
lymphopoietic cells (Kucia et al. 2004, Strahm et al. 2008). In addition, studies suggested 
that CXCR4 may be involved in the promotion of the metastatic potential of multiple 
tumor types, by activating migration and homing of tumors (Muller et al. 2001, Burger 
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and Kipps 2006, Oda et al. 2007, Akashi et al. 2008, Joyce and Pollard 2009). Moreover, 
results of a recently published study indicated that high levels of CXCR4 expression in 
rhabdomyosarcoma correlated with metastatic potential and poor prognosis (Diomedi-
Camassei et al. 2008). Therefore, blocking CXCR4 would be a promising approach in the 
treatment of metastatic rhabdomyosarcoma.  
To explore these possibilities, the author generated novel neutralizing antibodies, 
cVE199 and CF172, which are targeting VEGF-D and CXCR4, respectively. 
Additionally, the author investigated the in vitro activities and anti-metastatic efficacies 
of these two antibodies in animal models and their possible indications for human cancer 
treatment. 
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Chapter I: Blockade of VEGF-D by cVE199 Inhibits 
Lymphatic Metastasis in Neuroblastoma 
 
1. Introduction 
Cancer lethality is primarily associated with metastasis (Liotta 1992). In one type of 
metastasis, known as lymphatic metastasis, cancer cells spread to the lymph nodes. 
This type of metastasis serves as an important prognostic indicator for the disease state 
and lymphatic metastasis is correlated with poor prognosis in many cancer types 
(Grandi et al. 1985, de Manzoni et al. 1996, Qin and Tang 2002, Ghaferi et al. 2009, 
Lughezzani et al. 2009, Tuna et al. 2011). 
Multiple steps are required for lymphatic metastasis to occur, including detachment 
from the primary tumor mass; invasion into lymphatic vessels; transport through 
draining lymphatic vessels; and finally arrest, survival, and growth in the lymph nodes 
(Nguyen 2004, Pantel and Brakenhoff 2004). The first step is the formation of a new 
lymphatic vasculature from preexisting vessels in tumors, a process called 
lymphangiogenesis. Reliable markers for lymph vessels such as CD44-related 
hyaluronan receptor LYVE-1 revealed that tumor-associated upregulation of 
lymphangiogenesis is linked to increased lymphatic spread and poor prognosis in 
human cancers (Raica and Ribatti 2010). Hence, lymphangiogenesis has become the 
focus of interest in lymphatic metastasis research. 
A novel member of the vascular endothelial growth factor (VEGF) family, namely 
VEGF-D, has been implicated in the promotion of lymphangiogenesis. This molecule 
is synthesized as a proprotein. Following synthesis, the VEGF homology domain 
region is proteolytically cleaved and secreted into the extracellular environment. This 
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processing progressively increases the affinity of the molecule for its receptors 
(Stacker et al. 1999). In general, VEGF-D binds to the VEGF receptor (VEGFR)-2, 
expressed on both blood and lymphatic vessels, and VEGFR-3, predominantly 
expressed on lymphatic vessels and in some angiogenic tumor blood vessels (Achen 
et al. 1998, Saharinen et al. 2004). VEGFR-3 signaling is the primary factor 
responsible for the lymphangiogenic response to VEGF-D stimulation and leads to 
lymphangiogenesis in mouse models (Veikkola et al. 2001). Several experimental and 
clinical studies indicated positive correlations between VEGF-D expression, tumor 
lymphatic vessel density, and lymphatic metastasis (Achen and Stacker 2008). 
Moreover, a number of reports showed that higher VEGF-D expression correlates with 
poor prognosis in human tumors (White et al. 2002, Nakamura et al. 2003, Yokoyama 
et al. 2003, Juttner et al. 2006, Liu et al. 2008). Therefore, VEGF-D blockade seems 
to be a promising method to prevent lymphatic metastasis. 
To explore this possibility, the author generated a novel anti-VEGF-D monoclonal 
antibody, cVE199, and investigated its in vitro binding and neutralizing activity against 
human VEGF-D, its in vivo anti-lymph node metastasis efficacy against VEGF-D-
expressing tumors, and its possible indications for human cancer treatment. 
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2. Materials and Methods 
2.1. Anti-VEGF-D antibody generation  
Female BALB/c mice were immunized with recombinant VEGF-DΔNΔC, a 
polypeptide that contains amino acid residues 93 – 201 of human VEGF-D. After an 
increase in the serum titer was observed, splenocytes were prepared from the 
sacrificed mice and fused with myeloma cells. The resulting 5368 hybridoma cells 
were selected using a conventional HAT medium, IgG ELISA and binding activity to 
human VEGF-D. 
Chimeric antibody genes were then constructed by linking the cDNAs of the 
variable regions in the antibody’s heavy and light chains with the cDNAs of the 
constant regions from human IgG1 and kappa chains. The resultant chimeric 
antibodies were then heterologously expressed in HEK293 suspension culture and 
purified with protein A affinity chromatography and size-exclusion chromatography. 
 
2.2. Binding assay for cVE199 
For the binding assay, 96-well plates were coated with human VEGF-D (R&D 
Systems, USA) at 4°C overnight. After the plates were washed in 0.05% 
Tween20/PBS, they were incubated with Blocking One (Nacalai Tesque, Japan) for 
1 h. The plates were then incubated with monoclonal antibody at the required 
dilutions. Bound monoclonal antibody was detected with an anti-human Ig-HRP 
(Life Technologies Japan, Japan). The assay was quantified by reading absorbance at 
450 nm with an EnVision spectrophotometer (PerkinElmer, USA). 
 
2.3. The inhibitory activity of cVE199 against the binding of VEGF-D to 
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VEGFR3 
Stable human VEGFR-3-expressing CHO cells were aliquoted in a collagen type-I 
96-well plate (Becton Dickinson, USA) and incubated for 2 days at 37°C. Following 
this, 2% FBS/HBSS containing 2.5 μg/mL of His-tagged recombinant protein 
(VEGF-D or VEGF-C) and/or monoclonal antibody was added, and the cells were 
then incubated for 1 h. After 3-times washes with 0.05% Tween20/PBS, the cells 
were incubated with polyHistidine-HRP MAb (R&D Systems) for 1 h. The assay was 
quantified by reading absorbance at 405/620 nm with a multi-well plate reader (Bio-
Rad Laboratories, USA). 
 
2.4. Immunoprecipitation 
His-tagged human/mouse VEGF-D and His-tagged human VEGF-C were 
immunoprecipitated by cVE199 and Protein A agarose at 4°C overnight, followed by 
3-times washes with PBS. The samples were subsequently analyzed by western 
blotting. 
 
2.5. Neutralization assay with human lung lymphatic microvascular endothelial 
cells 
Human lung lymphatic microvascular endothelial cells (HMVEC-LLy) were 
obtained from Takara Bio (Japan), and maintained according to the suppliers’ 
instruction. MAZ-51 was purchased from Sigma-Aldrich Japan (Japan). For the assay, 
cells were aliquoted at 5 × 103 cells per well in a 96-well plate. After  incubation for 
16 h at 37°C, the cells were cultured in RPMI 1640 medium containing human 
VEGF-D and 0.1% FBS. Three days later, Cell Counting Kit-8 solution (Dojindo 
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Laboratories, Japan) was added. After the cells were incubated for several hours, 
absorbance at 450 nm was measured with an EnVision spectrophotometer 
(PerkinElmer).  
 
2.6. Cell culture 
Cell lines were obtained from the American Type Culture Collection (USA), the 
Deutsche Sammlung von Mikroorganismen und Zellkulturen (Germany), and Health 
Science Research Resources Bank (Japan). All cell lines were cultured according to 
the suppliers’ instructions. 
 
2.7. VEGF-D quantification by sandwich ELISA 
All VEGF-D quantification by ELISA in this study was performed by the Quantikine 
Human VEGF-D ELISA kit (R&D Systems). For the screening of VEGF-D-
expressing tumor cells, 100 μg of protein from each cell line was analyzed. For the 
detection of secreted VEGF-D, cells (5 × 105/well) were cultured in 6-well plates for 
72 h in the condition medium. Following this, the supernatants were analyzed. 
 
2.8. Gene expression analysis by Taqman 
RNA was isolated from cells using the RNeasy Mini Kit (Qiagen), and cDNAs were 
synthesized using the High Capacity RNA-to-cDNA Kit (Applied Biosystems). For 
real-time PCR analysis, 40 ng of cDNA was used for each reaction. Detection of the 
human VEGF-D gene was performed using Taqman probe (Hs01128661_m1, 
Applied Biosystems). The expression level of each gene was quantified against the 
house-keeping gene Gapdh (402869, Applied Biosystems) in the same treatment. 
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Reactions were run on the 7900HT Fast Real-Time PCR system (Applied 
Biosystems), and the calculation of the delta Ct value was performed using the 
Sequence Detection System (SDS) software v2.3. 
 
2.9. Western blotting 
Western blotting was performed as described previously (Ono et al. 2012). The 
following primary antibodies were used: His-tag (MBL, Japan), VEGF-D (Santa 
Cruz Biotechnology, USA), VEGFR-2, VEGFR-3, pY1175-VEGFR-2 (Cell 
Signaling, USA), pY1063/1068-VEGFR-3 (Cell Applications, USA), and tubulin-
alpha (AbD Serotec, UK). Signals were detected using ECL Plus (GE Healthcare, 
USA), followed by LAS-4000 (Fujifilm, Japan). Images were edited with 
MultiGauge (Fujifilm, Japan). 
 
2.10. Animal care 
All in vivo studies described here were conducted following the protocol approved 
by the Chugai Institutional Animal Care and Use Committee. All animal experiments 
were performed in accordance with the “Guidelines for the Accommodation and Care 
of Laboratory Animals” of Chugai Pharmaceutical Co. Ltd. All animals were housed 
in a pathogen-free environment under controlled conditions (temperature: 20–26°C, 
humidity: 40–70%, light-dark cycle: 12–12 h). Chlorinated water and irradiated food 
were provided ad libitum. The animals were allowed to acclimatize and recover from 
shipping-related stress for 1 week prior to the study. The health of the mice was 
monitored daily. 
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2.11. Mouse xenograft study 
SK-N-DZ_luc cells (5 × 106 in HBSS with BD MatrigelTM matrix; BD Biosciences, 
USA) were subcutaneously inoculated in the right flanks of 6-week-old, female, CB-
17 mice that had severe combined immunodeficiency (SCID; C.B-17/Icr-scid Jcl; 
Japan CLEA, Japan). After interperitoneal administration of luciferase substrate (65 
mg/kg; VivoGloTM Luciferin, Promega, USA), the anaesthetized mice were imaged 
using an in vivo imaging system (NightOWL L983; Berthold Technologies GmbH & 
Co KG, Germany). Luciferase signals were visualized and quantified using 
WinLight32 (Berthold Technologies GmbH & Co KG) imaging software for 
NightOWL. 
For the detection of lymph node metastasis, resected lymph nodes were sonicated 
and lysed with 100 μL of Cell Lysis Buffer (Cell Signaling) containing a complete 
protease inhibitor cocktail (Roche Diagnostics, Germany). The same amount of 
Bright-Glo luciferase assay system (Promega) was added. Assays were quantified by 
reading luminescence with an EnVision spectrophotometer (PerkinElmer). 
For lymph vessel staining, 3 tumors from each treatment group were excised on day 
14, weighed, and embedded in O.C.T compound (Tissuetek; Sakura Finetek Japan 
Co., Ltd., Japan), prior to being frozen in liquid nitrogen. Cryosections (5 μm) were 
fixed with ethanol and immunohistochemically stained for Lyve-1 using the Ventana 
automated immunostainer (Ventana Medical Systems Inc., USA). The following 
staining antibodies were used: polyclonal anti-mouse Lyve-1 antibody (RELIATech 
GmbH, Germany) and biotinized anti-rabbit-HRP antibody (Vector Laboratories, 
USA). The slides were counterstained with hematoxylin. 
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2.12. Immunohistochemical staining for VEGF-D 
Twenty-nine tissue samples from neuroblastoma patients were obtained using a 
commercially available tumor microarray (US Biomax, Inc., USA) and tumor 
sections (TriStar Technology Group, LLC., USA). Following this, 10% formalin-
fixed paraffin-embedded (FFPE) slides were stained with anti-VEGF-D antibody (sc-
101584, Santa Cruz Biotechnology), using a Ventana automated immunostainer 
(Ventana Medical Systems, Inc.), according to the manufacturer’s protocol. In brief, 
slides were pretreated with heat for 90 min by cell-conditioning solution 1 (Ventana 
Medical Systems, Inc.). The first antibody was incubated for 32 min at 37°C. Signals 
were visualized with ultraView Universal DAB detection kit (Ventana Medical 
Systems, Inc.). 
To evaluate VEGF-D expression levels, the number of positively stained cells per 
1000 tumor cells was counted. The expression was scored based on the percentage 
of positively stained cells. All cases were judged to be positive for VEGF-D when 
the proportion of immunoreactive tumor cells was greater than 30%. 
 
2.13. Statistical analyses 
All statistical tests in this study were performed using the Mann-Whitney U test. P < 
0.05 was considered to be significant. Statistical analyses were performed using the 
SAS preclinical package (version 8.2; SAS Institute Inc., USA). 
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3. Results 
3.1. cVE199, a human VEGF-D–specific monoclonal antibody  
First, the author generated a monoclonal human mouse chimeric antibody against 
human VEGF-D, which was designated cVE199, as described in Materials and 
Methods. 
The binding activity of cVE199 to human VEGF-D was determined by an antigen-
coated ELISA (Fig. 1-1a). The binding specificity against human VEGF-D was 
evaluated by immunoprecipitation using His-tagged human VEGF-D, His-tagged 
mouse VEGF-D, and His-tagged human VEGF-C, the most closely related protein to 
VEGF-D. As shown in Fig. 1-1b, cVE199 specifically bound to human VEGF-D.  
Next, the author investigated the inhibitory activity of cVE199 against the binding 
of human VEGF-D to VEGFR-3. The author found that cVE199 dose-dependently 
inhibited the binding of human VEGF-D to VEGFR-3 (Fig. 1-1c). Consistent with 
the binding specificity shown in Fig. 1-1b, cVE199 did not inhibit the binding of 
mouse VEGF-D or human VEGF-C to VEGFR-3 (Fig. 1-1d, e). 
 
3.2. cVE199 neutralizes the biological activity of human VEGF-D 
To evaluate the neutralizing activity of cVE199 against the biological activity of 
human VEGF-D, the author used human lymph endothelial cells derived from human 
lung tissues (HMVEC-Lly). HMVEC-Lly cells express VEGFR-3 (data not shown) 
and their proliferation was enhanced by VEGF-D. When HMVEC-Lly cells were 
incubated with cVE199, the VEGF-D-dependent growth of HMVEC-Lly was 
inhibited in a dose-dependent manner (Fig. 1-2a). 
The author then determined how cVE199 alters VEGF-D-derived signal 
transduction in HMVEC-Lly cells. VEGF-D induced the phosphorylation of 
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VEGFR-2 and VEGFR-3, which was inhibited by cVE199, when used at the highest 
concentration (5 μg/mL). At lower concentrations, cVE199 inhibited VEGFR-3, but 
not VEGF-D-induced VEGFR-2 phosphorylation (Fig. 1-2b). These data suggested 
that cVE199 preferentially inhibited VEGF-D/VEGFR-3 signaling, thereby 
inhibiting VEGF-D-dependent proliferation. To confirm these data, the author used 
MAZ-51, a commercially available VEGFR-3 kinase inhibitor (Kirkin et al. 2001). 
MAZ-51 completely inhibited VEGF-D-dependent proliferation of HMVEC-Lly 
(Fig. 1-2c). 
 
3.3. SK-N-DZ is a VEGF-D-expressing tumor cell line 
Many reports suggested that VEGF-D in tumor originated from the tumor cells 
themselves (White et al. 2002, Nakamura et al. 2003, Yokoyama et al. 2003, Juttner  
et al. 2006, Liu et al. 2008, Thelen et al. 2008). Therefore, in order to evaluate 
cVE199 activity against tumor progression, the author investigated VEGF-D-
expressing tumor cell lines. A VEGF-D ELISA using cell lysates was performed 
against 175 tumor cell lines. A neuroblastoma cell line, SK-N-DZ, expressed VEGF-
D (Table 1-1).  
To confirm VEGF-D expression in SK-N-DZ cells and to investigate the 
relationship between VEGF-D expression and neuroblastoma, 10 neuroblastoma cell 
lines, including SK-N-DZ, were analyzed in detail. The expression of VEGF-D 
mRNA was evaluated by real-time PCR. The author found that SK-N-DZ presented 
the highest VEGF-D mRNA expression among the 10 neuroblastoma cell lines, 
followed by KELLY and IMR-32 cells (Fig. 1-3a). Consistent with the mRNA 
expression patterns, VEGF-D precursor protein expression (about 50 kDa) was 
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strongly detected in SK-N-DZ cells and more weakly detected in KELLY and IMR-
32 cells using western blot (Fig. 1-3b). The detection specificity in this assay was 
confirmed by using a VEGF-D siRNA (data not shown). Although these results were 
obtained by using tumor cell lysates, VEGF-D is a secreted protein and, thus, the 
author also assessed the presence of the secreted form of VEGF-D in the supernatant 
of the neuroblastoma cell lines using a VEGF-D ELISA. VEGF-D was detectable 
only in the supernatant of SK-N-DZ cells (Fig. 1-3c). These data indicate that the 
SK-N-DZ cell line is a VEGF-D-expressing tumor cell line. 
The author further confirmed VEGF-D expression in SK-N-DZ xenograft tumors 
by VEGF-D immunohistochemistry (IHC). To do so, the author generated a HEK293 
cell line stably expressing human VEGF-D (293-VEGF-D). VEGF-D expression in 
293-VEGF-D was confirmed by VEGF-D ELISA (Fig. 1-4a). The specificity of the 
VEGF-D staining was confirmed by comparing the staining of 293-VEGF-D with 
that of parental HEK293 cells, (Fig. 1-4b). In addition, SH-SY5Y xenograft tumors 
were also used as negative controls for VEGF-D staining, because SH-SY5Y did not 
express VEGF-D in my in vitro analysis (Fig. 1-3b, c). As shown in Figure 1-5a, SK-
N-DZ xenograft tumors stained for VEGF-D, while SH-SY5Y xenograft tumors were 
negative for VEGF-D. Furthermore, the author evaluated the status of lymph vessels 
in these xenograft tumors with a mLyve-1 IHC assay because VEGF-D is a 
lymphangiogenic factor. Consistent with the VEGF-D staining pattern, the SK-N-DZ 
xenograft tumors stained positive for mLyve-1, while SH-SY5Y xenograft tumors 
were negative for mLyve-1 (Fig. 1-5b). 
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3.4. cVE199 inhibited in vivo lymphatic metastasis of SK-N-DZ 
The author next investigated the in vivo effect of cVE199 against lymphatic 
metastasis of SK-N-DZ cells in mice. To do so, the author generated a SK-N-DZ cell 
line stably expressing luciferase (SK-N-DZ-luc) in order to conduct bioimaging in 
mice (Fig. 1-6a). Compared to the SK-N-DZ parental cells, the SK-N-DZ-luc cells 
exhibited similar levels of VEGF-D expression in vitro (Fig. 1-6b). Furthermore, the 
in vitro proliferation of SK-N-DZ-luc cells did not differ from that of SK-N-DZ cells 
(Fig. 1-6c). In addition, the author evaluated VEGFR-2 and VEGFR-3 expression in 
SK-N-DZ-luc cells to consider the autocrine effect of VEGF-D. SK-N-DZ-luc cells 
did not express either VEGFR-2 or VEGFR-3 (Fig. 1-7). 
Next, an in vivo efficacy study was performed by inoculating SK-N-DZ-luc cells 
into SCID mice and by a twice-weekly intravenous administration of 10 mg/kg 
cVE199 (n = 10). On the 14th day after the first administration, a slight difference in 
the tumor size of SK-N-DZ-luc in the primary lesion was observed between the 
cVE199-injected mice and the vehicle-injected mice (Fig. 1-8a, b). In contrast, SK-
N-DZ-luc cell metastasis into the ipsilateral lymph nodes (lymphatic metastasis) was 
significantly decreased by cVE199 injection on the 14th day after the first 
administration (p < 0.05, Fig. 1-5c). The individual data shown in Fig. 1-8c (the 
amount of photons and the number of metastasized SK-N-DZ-luc cells) are presented 
in Fig. 1-9. In order to evaluate the association of lymph vessels with the reduction 
of metastasis into the lymph nodes, the author then analyzed lymph vessels in 
primary tumors using mLyve-1 IHC. As shown in Fig. 1-8d, the 
immunohistochemical signal for mLyve-1 in cVE199-injected xenograft tumors was 
much weaker than that in control xenograft samples. In contrast, the 
  
22 
 
immunohistochemical signal for mCD31 was not different between the 2 groups. 
This indicated that cVE199 did not affect blood vessels within the primary SK-N-
DZ-luc tumors (Fig. 1-10). These data further indicate that cVE199 decreased SK-
N-DZ-luc cell lymphatic metastasis by inhibiting lymph vessel formation. 
 
3.5. Neuroblastoma is a potential indication for cVE199 
Since only a neuroblastoma cell line, SK-N-DZ, abundantly expressed VEGF-D in 
my in vitro culture analysis, the author investigated VEGF-D expression in tumor 
tissues from patients with neuroblastoma. Twenty-nine commercially available 
neuroblastoma specimens were analyzed by IHC, as described in Materials and 
Methods. Using the criteria for VEGF-D immunohistochemical evaluation, VEGF-
D-positive staining was detected in 11 cases (37.9%). Typical examples of VEGF-D-
positive and VEGF-D-negative staining are presented in Fig. 1-11a and b respectively. 
These results indicate that some patients with neuroblastoma express VEGF-D. 
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4. Discussion  
Lymphatic spread is an important clinical determinant in the prognosis of many 
cancers. Therefore, therapeutic modalities capable of inhibiting lymphatic spread 
should be beneficial for the treatment of many cancers. VEGF-D is implicated in 
lymphatic spread through the promotion of lymphangiogenesis in human cancers. In 
addition, high VEGF-D expression correlates with poor prognosis in many cancers. 
These findings suggest that an anti-VEGF-D antibody would be a promising agent 
for cancer treatment. 
In this study, the author generated a novel anti-VEGF-D chimeric monoclonal 
antibody, cVE199, which specifically binds to and neutralizes human VEGF-D. 
Using HMVEC-Lly cells, the author showed that cVE199 preferentially inhibited the 
VEGF-D/VEGFR-3 signaling pathway rather than the VEGF-D/VEGFR-2 signaling 
pathway (Fig. 1-2b). A recent study showed that N-terminal residues of VEGF-D are 
important for VEGF-D binding and activation of VEGFR-3, but not for that of 
VEGFR-2 (Leppanen et al. 2011). This finding suggested that cVE199 binds to N-
terminal residues of VEGF-D, thereby preferentially inhibiting VEGF-D/VEGFR-3 
signaling. 
In a xenograft study to evaluate the in vivo effect of cVE199, the author used SK-
N-DZ cells that express VEGF-D endogenously, though previous studies used 
VEGF-D-transfected cell lines. This approach is important because it has a higher 
clinical relevance compared to overexpression experiments. My results indicated that 
cVE199 significantly decreased lymph node metastasis of SK-N-DZ cells with 
reduction of lymphangiogenesis, strongly supporting previously published 
conclusions drawn from VEGF-D overexpressing in vivo studies. These reports 
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largely attributed the metastatic action of VEGF-D to an induction of 
lymphangiogenesis. For instance, VEGF-D stimulated lymphangiogenesis when the 
molecule was overexpressed in the skin keratinocytes (Veikkola et al. 2001). It 
promoted the development of lymphatics and lymph node metastasis when 
overexpressed in tumors (Stacker et al. 2001, Thelen et al. 2008). 
In this study, cVE199 did not alter blood vessels in the primary SK-N-DZ-luc 
xenograft tumors. Although the VEGF-D/VEGFR-3 pathway is known to play a role 
not only in tumor lymphangiogenesis, but also in pathological angiogenesis, the 
VEGF-A/VEGFR-2 signal is known as the predominant regulator of physiological 
and tumor angiogenesis (Bergers and Benjamin 2003). The author found that SK-N-
DZ-luc cells expressed VEGF-A (Fig. 1-12). In addition, VEGFR-3 kinase inhibitor 
or VEGFR3-Ig, a potent inhibitor of VEGF-C/VEGF-D signaling, did not always 
affect tumor angiogenesis (Wong et al. 2005, Yashiro et al. 2009). These data suggest 
that the contribution of VEGF-D/VEGFR-3 signaling to tumor angiogenesis is 
affected by in vivo circumstances such as VEGF-A expression. Furthermore, these 
findings might explain the reason for the ineffectiveness of cVE199 on tumor 
angiogenesis in SK-N-DZ-luc xenograft tumors. 
Because cVE199 did not affect tumor growth (Fig. 1-8a, b) or angiogenesis (Fig. 1-
10), it seems that cVE199 inhibits lymph node metastasis of SK-N-DZ-luc cells by 
inhibiting lymphangiogenesis. Thus, my findings also support previously published 
data, which showed that formation of a dense lymphatic network that facilitates 
metastatic tumor spread by increasing the likelihood that tumor cells will leave the 
primary tumor site and invade the lymphatics (Detmar and Hirakawa 2002). 
One of the most important findings was that cVE199 inhibits lymphatic metastasis 
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in an experimental neuroblastoma model (Fig. 1-8) and that VEGF-D was expressed 
in some human neuroblastomas (Fig. 1-11), implicating VEGF-D in neuroblastoma 
lymphatic metastasis. These findings further suggest cVE199 as a possible 
therapeutic antibody for neuroblastoma. Although many lower-stage neuroblastomas 
regress completely or differentiate into benign ganglioneuroblastoma without 
treatment, metastatic neuroblastoma (stage IV) in children over 1 year of age is lethal 
for most patients despite aggressive multimodality therapy (Brodeur 2003, Maris et 
al. 2007, Maris 2010, Modak and Cheung 2010). Therefore, new therapeutic agents 
for neuroblastoma are still necessary and my finding that cVE199 has potential as a 
therapeutic antibody for neuroblastoma is of significance.  
In conclusion, the results of the present study implicate VEGF-D in the promotion 
of neuroblastoma lymphatic metastasis and identify cVE199 as a potential 
therapeutic antibody against neuroblastoma to prevent this process.  
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5.  Tables 
 
Table 1-1. Screening of VEGF-D expressing tumor cells   
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6.  Figures  
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Fig. 1-1. Reaction specificity of cVE199 against rhVEGF-D.  
(a) The binding activity of cVE199 to rhVEGF-D was measured by an ELISA. The 
various concentrations of cVE199 (■) and hIgG1 control (△) were reacted to plated 
hVEGF-D. Binding was detected by HRP-labeled anti-human IgG. (b) The binding 
specificity of cVE199 to hVEGF-D was evaluated by the immunoprecipitation as 
described in Materials and Methods. (c–e) The inhibitory activity of cVE199 against the 
binding of (c) hVEGF-D, (d) mVEGF-D, and (e) hVEGF-C to VEGFR3 was measured 
using a cell-based assay. His-tagged protein was incubated with VEGFR3 stably 
expressing CHO cells, in the presence or absence of various concentrations of cVE199 
(■) and hIgG1 control (△). Binding was detected by polyHistidine-HRP MAb. The 
absorbance when 1.25 or 0 μg/mL of recombinant protein was added with no antibody is 
indicated by the (+) or (-) dotted lines, respectively. Points indicate the mean ± SD (n = 
3). 
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Fig. 1-2. Neutralization activity of cVE199 against rhVEGF-D.  
The neutralization activity of cVE199 for VEGF-D was measured using HMVEC-Lly 
cells. (a) A total of 500 ng/mL of VEGF-D was pre-incubated with serially diluted 
cVE199 (■) and hIgG1 control (△) for 15 min at 37°C, and added to HMVEC-Lly cells 
for 72 h. The number of living cells was then measured using a Cell Counting Kit-8 
solution. The cell number when 500 or 0 ng/mL of VEGF-D was added with no antibody 
is indicated by the (+) or (-) dotted line, respectively. (b) HMVEC-Lly cells were 
incubated with cVE199 and VEGF-D. After 10 min, the cells were harvested and 
analyzed by western blotting with phospho-VEGFR-2 and phospho-VEGFR-3 antibodies. 
(c) MAZ-51 was used instead of cVE199. Assay was conducted by the same method as 
(a). All points indicate the mean ± SD (n = 3).   
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Fig. 1-3. Analysis of VEGF-D expression in neuroblastoma cell lines.  
(a) VEGF-D mRNA expression in 10 neuroblastoma cell lines was analyzed by the 
Taqman assay (n = 3 for each cell line). Data were normalized to Gapdh. (b) Expression 
of VEGF-D protein in 10 neuroblastoma cell lines was analyzed by western blot using 
anti-VEGF-D antibody. (c) Each cell line was cultured for 72 h in the condition medium. 
The VEGF-D concentration in the medium was quantified using the VEGF-D ELISA kit 
(n = 3 for each cell line). All values are expressed as the mean ± SD.   
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Fig. 1-4. Evaluation of the specificity of VEGF-D immunohistochemical analysis.  
(a) VEGF-D expressing HEK293 cells (293-VEGF-D) were generated by 
lectroporation with the human VEGF-D expression vector. VEGF-D expression was 
confirmed by Quantikine Human VEGF-D ELISA kit (n = 3 for each cell line). (b) 
Specificity of immunohistochemical analysis for VEGF-D was evaluated by staining 
comparison with HEK293 and 293-VEGF-D. FFPE slides were stained with anti-
VEGF-D antibody by a Ventana automated immunostainner.  
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Fig. 1-5. Analysis of VEGF-D expression in neuroblastoma xenograft.  
Expression of VEGF-D in neuroblastoma xenograft was evaluated by 
immunohistochemistry with anti-VEGF-D antibody. FFPE slides were stained by a 
Ventana automated immunostainer. (a) SK-N-DZ showed an immunohistochemical 
signal for VEGF-D (b) and SH-SY5Y showed immunonegativity to VEGF-D. 
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Fig. 1-6. Comparison of profile between SK-N-DZ and SK-N-DZ-luc cells. 
 (a) SK-N-DZ-luc was generated by infection of lentivirus with luciferase expression 
region. Luciferase activity was confirmed by Bright-Glo luciferase assay system (n = 3 
for each cell line). (b) Comparison of secreted VEGF-D level between SK-N-DZ and 
SK-N-DZ-luc cells was analyzed by Quantikine Human VEGF-D ELISA kit (n = 3 for 
each cell line). (c) Comparison of in vitro proliferation ability between SK-N-DZ and 
SK-N-DZ-luc cells was quantified by Cell Count Kit (n = 3 for each cell line). All 
values are expressed as the mean ± SD. 
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Fig. 1-7. Expression of VEGFR-2 and VEGFR-3 in SK-N-DZ-luc cells.  
(a) VEGFR-2 and (b) VEGFR-3 expression on cell surface were analyzed by FACS 
with anti-VEGFR-2 and VEGFR-3 antibody (R&D systems). HMVEC-Lly was used as 
a positive control cell. 
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Fig. 1-8. In vivo effect of cVE199 against VEGF-D expressing neuroblastoma model. 
(a and b) Antitumor effect of cVE199 against SK-N-DZ primary lesion was evaluated by 
bioimaging technique. Mice bearing SK-N-DZ were administered with 10 mg/kg of 
cVE199 at biw regimen for 2 weeks. Tumor size was measured by administration of 
luciferase substrate and detection of the photons. Data are shown by a box-and-whisker 
plot. Statistical tests were performed using the Wilcoxon test. (c) Anti-metastasis activity 
of cVE199 against SK-N-DZ was evaluated by detection of photons from lysed lymph 
nodes. Data are shown by a box-and-whisker plot. Statistical tests were performed using 
the Wilcoxon test. (d) The presence of lymph vessels in the primary tumors of SK-N-DZ 
was analyzed by mLyve-1 immunostaining. FFPE slides were stained with an anti-mouse 
Lyve-1 antibody using a Ventana automated immunostainer. 
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Fig. 1-9. Plot of photons and SK-N-DZ-luc number in each mouse shown in Fig. 1-
8. 
(a) The amount of photons in each mouse shown in Fig. 5c was plotted. (b) The 
number of SK-N-DZ-luc cells in each mouse shown in Fig. 5c was plotted. This cell 
number was calculated based on the result in Fig. S2a showing the relationship between 
the number of SK-N-DZ-luc and photons. All statistical tests were performed using the 
Wilcoxon test. 
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Fig. 1-10. Immunohistochemical analysis of mCD31 in SK-N-DZ-luc xenograft.  
The presence of blood vessels in the primary tumors of SK-N-DZ was analyzed by CD31 
immunostaining. FFPE slides were stained with an anti-mouse CD31 antibody (BD 
Biosciences) using a Ventana automated immunostainer. 
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Fig. 1-11. Immunohistochemical analysis of VEGF-D in neuroblastomas.  
Expression of VEGF-D in neuroblastoma specimens was evaluated by 
immunohistochemistry with anti-VEGF-D antibody. FFPE slides were stained by a 
Ventana automated immunostainer. According to the criteria for VEGF-D 
immunohistochemical evaluations as described in Materials and Methods, (a) tumor 
cells showed immunohistochemical signal for VEGF-D and (b) the tumor cells showed 
immunonegativity to VEGF-D. 
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Fig. 1-12. Expression of VEGF-A in SK-N-DZ-luc cells.  
Secreted VEGF-A level in SK-N-DZ-luc cells was analyzed by Quantikine Human 
VEGF-A ELISA kit (R&D systems). Assay was performed by n = 3. All values are 
expressed as the mean ± SD. 
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Chapter II: Blockade of CXCR4 by CF172 Inhibits 
Rhabdomyosarcoma Metastasis 
 
1.  Introduction 
Rhabdomyosarcoma is the most common soft tissue sarcoma reported in children. 
During the last 30 years, the introduction of multimodal therapy has significantly 
improved cancer survival, with a cure rate of approximately 70% for patients 
exhibiting localized disease. Unfortunately, at least 15% of children with 
rhabdomyosarcoma exhibit metastatic disease and the prognosis for metastatic 
rhabdomyosarcoma has not improved significantly in the last 15 years, with an 
overall cure rate below 30% (Koscielniak et al. 1992, Crist et al. 2001, Breneman et 
al. 2003, Stevens et al. 2005, Oberlin et al. 2008, Malempati and Hawkins 2012). 
Therefore, there is a critical need to develop therapeutics to treat metastatic 
rhabdomyosarcoma. 
Organ-specific patterns of metastasis associated with different tumor types were 
first described by Paget’s “seed-and-soil” hypothesis (Paget 1989). This hypothesis 
states that tumor cells may form metastases at sites that (a) chemoattract and arrest 
tumor cells by locally secreted factors and (b) provide a favorable microenvironment 
for tumor cell survival and growth (Kucia et al. 2004). Chemokines are small pro-
inflammatory chemoattractant proteins that bind to G-protein coupled receptors 
present on the cell surface of target cells. These chemokines are major regulators of 
cell trafficking, survival, and growth (Rossi and Zlotnik 2000, Balkwill 2004, Strahm 
et al. 2008). The chemokine, stromal cell-derived factor 1 (SDF1), and its receptor, 
CXC chemokine receptor-4 (CXCR4), play a unique role in homing and migration 
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of hematopoietic and lymphopoietic cells (Kucia et al. 2004, Strahm et al. 2008). In 
addition, studies suggested that CXCR4 may be involved in the promotion of 
metastatic potential in multiple tumor types, by activating migration and homing of 
tumors (Muller et al. 2001, Burger 2006, Oda et al. 2007, Akashi et al. 2008, Joyce 
and Pollard 2009). Moreover, results of a recently published study indicated that high 
levels of CXCR4 expression in rhabdomyosarcoma correlated with metastatic 
potential and poor prognosis (Diomedi-Camassei et al. 2008). Therefore, blocking 
CXCR4 would be a promising approach in the treatment of metastatic 
rhabdomyosarcoma. 
To explore this possibility, the author generated a novel anti-CXCR4 monoclonal 
antibody, CF172, and investigated its in vitro binding and neutralizing activity 
against human CXCR4 and its anti-metastatic efficacy against rhabdomyosarcoma 
cell lines. 
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2.  Materials and Methods 
2.1. Anti-CXCR4 antibody generation 
Female Balb/c mice were immunized with CXCR4-stably expressed Ba/F3 cells. 
After an increase was observed in the serum titer of the anti-CXCR4 antibody, 
splenocytes were prepared from the sacrificed mice and fused with myeloma cells. 
The resulting 51656 hybridoma cells were selected using a conventional HAT 
medium, IgG ELISA and binding activity to human CXCR4. 
Anti-CXCR4 antibody was typically produced from the culture of hybridoma cells, 
followed by purification with protein A affinity chromatography and subsequent size-
exclusion chromatography. 
 
2.2. Flow cytometry 
The binding activity of CF172 for CXCR4 expressed on cell surfaces was examined 
by flow cytometry. Cells were stained on ice for 30 min with either CF172 or control 
mouse IgG2b (R&D Systems, USA). Becton Dickinson Stained cells were then 
analyzed using a FACSCalibur cell analyzer (Becton Dickinson). 
 
2.3. Neutralization assay 
Neutralization activity against CXCR4 was evaluated using the Tango CXCR4-bla 
U2OS cell-based assay system (Invitrogen, USA). For the assay, serially diluted 
antibody was pre-incubated with Tango CXCR4-bla U2OS for 30 min at 37°C. SDF1 
(4 nM) was added to the cells, which were subsequently incubated for 5 h at 37°C. 
Cells were then loaded with LiveBLAzer FRET B/G substrate (Invitrogen) for 2 h at 
room temperature. Fluorescence spectra were acquired at 460 nm and 530 nm 
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(excitation wavelength 409 nm), using an EnVision Multilabel Plate Reader 
(PerkinElmer, USA). 
For the neutralization assay against CXCR2, a PathHunter eXpress β-Arrestin 
GPCR assay system was used (DiscoveRx, USA). PathHunter CHO-K1 CXCR2 
cells were incubated overnight at 37°C followed by 90 min incubation in the presence 
of CXCL8 (1.25 nM) and serially diluted antibody, followed by 1 h incubation with 
PathHunter detection reagent. Plates were then analyzed for a chemiluminescent 
signal using the EnVision Multilabel Plate Reader (PerkinElmer). 
 
2.4. Cell cultures 
SJCRH30, A-204 and A-673 were obtained from the American Type Culture 
Collection (USA). RD was purchased from DS Pharma Biomedical Co., Ltd (Japan). 
RH30 cells were obtained from the Deutsche Sammlung von Mikroorganismen und 
Zellkulturen (Germany). All cell lines were cultured according to the suppliers’ 
instructions. 
 
2.5. cAMP ELISA 
SJCRH30 cells were grown as confluent monolayers in a 96-well plate. Before 
stimulation, cells were incubated for 30 min with monoclonal antibody and 1 mM 
IBMX (Sigma-Aldrich Japan, Japan). Cells were stimulated with 100 nM SDF1 
(R&D systems) diluted in HBSS/IBMX for 10 min, after which they were incubated 
for an additional 10 min with 25 μM forskolin (Sigma-Aldrich Japan) to stimulate 
cAMP production. Then, cells were washed 2 times in ice-cold HBSS/IBMX and 
solubilized, and cAMP was assayed using the cAMP Parameter Assay Kit (R&D 
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systems). 
 
2.6. Migration assay 
Both CIM-Plate and the xCELLigence System RTCA DP analyzer (Roche 
Diagnostics, Germany) were used to monitor real-time migrations. The 
xCELLigence system is an electrical impedance-based system that allows for real-
time cell monitoring (Ke et al. 2011). For this assay, 4 × 104 cells with antibodies, in 
growth medium, were seeded into the upper chamber of a CIM-Plate. The upper 
chamber was then placed on the lower chamber of the CIM-Plate which contained 
10 nM SDF1. Cell migration was monitored for up to 7 h. Data were analyzed using 
RTCA software (Roche Diagnostics). 
 
2.7. Western blotting 
Western blotting was performed as described previously (Kashima et al. 2012). The 
following primary antibodies were used: anti-CXCR4 (Sigma-Aldrich Japan, Japan) 
and anti-tubulin-alpha (AbD Serotec, UK). Signals were detected using Chemi-Lumi 
One Super (Nacalai Tesque, Kyoto, Japan) with imaging on an LAS-4000 systems 
(Fujifilm, Japan). Images were edited with MultiGauge (Fujifilm). 
 
2.8. Animal care 
All in vivo studies described here were conducted following a protocol approved by 
the Chugai Institutional Animal Care and Use Committee. All animal experiments 
were performed in accordance with the “Guidelines for the Accommodation and Care 
of Laboratory Animals” of Chugai Pharmaceutical Co. Ltd. All animals were housed 
in a pathogen-free environment under controlled conditions (temperature, 20–26°C; 
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humidity, 40–70%; light-dark cycle, 12–12 h). Chlorinated water and irradiated food 
were provided ad libitum. The animals were allowed to acclimatize and recover from 
shipping-related stress for 1 week prior to the study. The health of the mice was 
monitored daily. 
 
2.9. Mouse xenograft study for peritoneal metastasis 
SJCRH30-luc cells (2 × 106 in HBSS) were intraperitoneally injected into nude mice 
(CAnN.Cg-Foxn1<nu>/CrlCrlj nu/nu, Charles River Japan). On the same day of 
SJCRH30-luc inoculation, 25 mg/kg CF172 was intravenously injected in a single 
shot. On day 5 after interperitoneal administration of luciferase substrate (65 mg/kg; 
VivoGloTM Luciferin, Promega, USA), the anesthetized mice were imaged using an 
in vivo imaging system (NightOWL L983; Berthold Technologies GmbH & Co KG, 
Germany). Luciferase signals were visualized and quantified using IndiGOTM ver. 
2.0.0.22 (Berthold Technologies GmbH & Co KG) imaging software for NightOWL. 
 
2.10. Mouse xenograft study for tumor growth and lymph node metastasis 
To evaluate tumor growth inhibition in vivo, SJCRH30-luc cells (3 × 106 in HBSS) 
were implanted subcutaneously into the right flank of nude mice (CAnN.Cg-
Foxn1<nu>/CrlCrlj nu/nu, Charles River Japan). Tumor volume (TV) was calculated 
using the formula: TV = ab2 ⁄ 2, where a and b represent tumor length and width, 
respectively. Once the tumors had reached a volume of approximately 100 mm3, 
animals were randomly assigned to two groups (n = 5) and treatment was initiated. 
Twice-weekly intravenous administration of CF172 (25 mg/kg per injection) was 
performed for 14 days.  
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For the detection of lymph node metastasis, the resected lymph nodes were 
sonicated and lysed with 100 μL of Cell Lysis Buffer (Cell Signaling, USA) 
containing a complete protease inhibitor cocktail (Roche Diagnostics, Germany). 
The same amount of Bright-Glo luciferase assay system (Promega) was added. 
Assays were quantified by reading luminescence using EnVision spectrophotometer 
(PerkinElmer). 
 
2.11. Statistical analyses 
Statistical tests in this study were performed using Student's t-test or the Mann-
Whitney U test. P < 0.05 was considered significant. Statistical analyses were 
performed using the SAS preclinical package (version 8.2; SAS Institute Inc., USA).  
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3. Results 
3.1. CF172 specifically binds to and neutralizes human CXCR4 
First, the author generated a monoclonal antibody against human CXCR4, which was 
designated CF172, as described in the Materials and Methods. 
The binding activity of CF172 to human CXCR4 was determined by FACS using 
human CXCR4-expressing CHO cells (Fig. 2-1a). To evaluate the binding specificity 
of CF172 against human CXCR4, the author conducted FACS analysis using CHO 
cells expressing mouse CXCR4 and human CXCR2 (The protein most closely related 
to CXCR4). Results indicated that CF172 did not bind to either mouse CXCR4- or 
human CXCR2-expressing CHO cells (Fig. 2-1b and 2-1c, respectively). 
Next, the author investigated the neutralizing activity of CF172 against human 
CXCR4 by using cell-based assays, as described in Materials and Methods. CF172 
dose-dependently inhibited SDF1-mediated signaling of human CXCR4 (Fig. 2-2a). 
Additionally, CF172 did not inhibit CXCL8-mediated signaling of human CXCR2 
(Fig. 2-2b), which was consistent with the observed binding specificity presented in 
Fig. 2-1.  
 
3.2. SJCRH30 and RH30 are CXCR4-expressing rhabdomyosarcoma cell lines 
Next, to investigate CXCR4 expression on the cell surface of rhabdomyosarcoma 
cells, the author conducted FACS analysis of CF172 using 5 different 
rhabdomyosarcoma cell lines. SJCRH30 and RH30 cells expressed human CXCR4 
and the expression levels of SJCRH30 cells were higher than those of RH30 (Fig. 2-
3a). To confirm this expression pattern, the author performed western blot analysis 
(Fig. 2-3b). Consistent with the cell surface expression pattern (Fig. 2-3a), SJCRH30 
cells exhibited the highest CXCR4 protein expression among the 5 
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rhabdomyosarcoma cell lines. 
 
3.3. CF172 inhibits the biological activity of human CXCR4 in SJCRH30 cells 
To evaluate the inhibitory activity of CF172 against the biological activity of CXCR4 
in rhabdomyosarcoma cells, the author further analyzed SJCRH30 cells, which 
exhibited the highest CXCR4 expression (Fig. 2-3a and 2-3b), by determining their 
response to SDF1. 
CXCR4 is known to transduce signals via the Giα-subunit of the heterotrimeric G 
protein complex, after stimulation by SDF1 (Rollins 1997). The prototypic function 
of Giα proteins is the binding to and inhibition of adenylyl cyclase-mediated cAMP 
production (Neves et al. 2002, Dwinell et al. 2004). To determine if this was also the 
case in human rhabdomyosarcoma cells, the author assessed whether activation of 
CXCR4 with SDF1 could block adenylyl cyclase-mediated cAMP production in 
SJCRH30 cells. SJCRH30 cells were first incubated with SDF1 and then stimulated 
with forskolin, to upregulate cAMP production. As observed in Fig. 2-4a 
(comparison of (+) and (-) dotted line), SDF1 inhibited the forskolin-stimulated 
cAMP responses in SJCRH30 cells. The subsequent addition of CF172 abrogated the 
inhibition of forskolin-stimulated cAMP production by SDF1 in a dose-dependent 
manner (Fig. 2-4a).   
CXCR4/SDF1 signaling in tumor cells is known to enhance migration activity 
(Muller et al. 2001, Burger and Kipps 2006, Oda et al. 2007, Akashi et al. 2008, Joyce 
and Pollard 2009). To determine if this was also the case in human 
rhabdomyosarcoma cells, the author assessed whether CXCR4 activation by SDF1 
enhanced SJCRH30 cell migration activity. My results indicated that SDF1 enhanced 
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the migration activity of SJCRH30 cells (Fig. 2-4b). Addition of CF172 inhibited the 
SDF1-induced migration activity of SJCRH30 cells (Fig. 2-4b). To determine 
whether CF172 specifically inhibited migration and did not affect the proliferation 
of SJCRH30 cells, the author next investigated the effect of this agent on the 
proliferation of SJCRH30 cells. As shown in Fig. 2-5, serial concentrations of CF172 
did not inhibit the proliferation of SJCRH30 cells in the presence or absence of SDF1. 
 
3.4. CF172 inhibited in vivo peritoneal metastasis and lymph node metastasis of 
SJCRH30 cells 
The author finally investigated the in vivo effect of CF172 against metastasis using 
SJCRH30 cells. Although there are many types of tumor metastasis, the author 
selected peritoneal metastasis and lymph node metastasis for evaluation because both 
peritoneal metastasis and lymph node metastasis are clinically observed with 
rhabdomyosarcoma. For these analyses, the author generated a SJCRH30 cell line 
stably expressing luciferase (SJCRH30-luc) in order to conduct bioimaging in mice 
(Fig. 2-6a). Compared to the SJCRH30 parental cells, the SJCRH30-luc cells 
exhibited similar levels of CXCR4 expression in vitro (Fig. 2-3 and Fig. 2-6b). In 
addition, the author evaluated SDF1-induced migration activity of SJCRH30-luc 
cells and found that SJCRH30-luc cell migration was induced by SDF1, while CF172 
inhibited it (Fig. 2-6c).  
The author then attempted to generate an experimental peritoneal metastasis model 
of rhabdomyosarcoma by intraperitoneally injecting SJCRH30-luc cells into nude 
mice. On the 5th day after the inoculation of SJCRH30-luc cells, the author detected 
photons in the peritonea of inoculated nude mice. The amount of photons was not 
reduced by washing of the peritonea with PBS (data not shown). Therefore, the 
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author concluded that these results validated the experimental peritoneal metastasis 
model of rhabdomyosarcoma. 
The author then performed an in vivo efficacy study involving intravenous 
administration of 25 mg/kg CF172, using the model described above. Briefly, 
SJCRH30-luc cells were intraperitoneally injected into nude mice. On the same day, 
CF172 (25 mg/kg) was intravenously injected as a single shot. On the 5th day, 
peritoneal metastasis was evaluated by detection of photons, using bioimaging. My 
results indicated a significant reduction in the amount of photons in the CF172-
injected mice when compared with the vehicle-injected mice (p < 0.05, Fig. 2-7a). 
The individual photos of mice on day 5 are presented in Fig. 2-5b (n = 7 in the 
vehicle-injected group and n = 9 in the CF172-injected group). In addition, the author 
evaluated the concentration of SDF1 in ascites fluid before and after the inoculation 
of SJCRH30-luc cells. As shown in Fig. 8, the SDF1 concentration before the 
inoculation of SJCRH30-luc cells did not differ from that after the inoculation of 
SJCRH30-luc cells. These data indicate that inoculation of SJCRH30-luc cells had 
little impact on the SDF1 concentration in ascites fluid. Thus, the effect of CF172 
against peritoneal metastasis of SJCRH30-luc cells did not involve a dramatic change 
in SDF1 induced by inoculation of SJCRH30-luc cells. 
The author then examined whether CF172 inhibited lymph node metastasis of 
SJCRH30-luc cells. SJCRH30-luc cells were implanted subcutaneously into the right 
flank of nude mice. Once the tumors reached a volume of approximately 100 mm3, 
the mice were randomized into two groups (n = 5), and were administered CF172 (25 
mg/kg) twice-weekly intravenously for 14 days. There was little difference in the size 
of the tumors formed by SJCRH30-luc cells in the primary lesion between the 
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CF172-injected and the vehicle-injected mice (Fig. 2-9a). In contrast, as shown in 
Fig. 2-9b, CF172 significantly inhibited lymph node metastasis of SJCRH30-luc cells 
in this model. These data further indicate that CF172 decreased the metastasis of 
SJCRH30-luc cells by inhibiting tumor migration from the primary lesion without 
affecting tumor volume. 
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4.  Discussion 
Tumor metastasis is an important clinical determinant in the prognosis of many 
tumors, while the overall cure rate of metastatic rhabdomyosarcoma remains very 
low, compared to localized rhabdomyosarcoma (Koscielniak et al. 1992, Crist et al. 
2001, Breneman et al. 2003, Stevens et al. 2005, Oberlin et al. 2008, Malempati and 
Hawkins 2012). Therefore, therapeutic modalities capable of inhibiting tumor 
metastasis would be highly beneficial in the treatment of rhabdomyosarcoma. High 
CXCR4 expression correlates with metastatic incidence and poor prognosis of 
rhabdomyosarcoma (Diomedi-Camassei et al. 2008), suggesting that the 
SDF1/CXCR4 axis is very important for the metastatic process. These findings also 
suggest that an anti-CXCR4 antibody would be a promising agent for metastatic 
rhabdomyosarcoma treatment. 
In this study, the author generated a novel anti-CXCR4 monoclonal antibody, 
CF172, which specifically binds and neutralizes human CXCR4. Several studies 
indicated that SDF1 activates downstream signaling pathways by interacting with the 
second extracellular loop of CXCR4 (Doranz et al. 1999, Brelot et al. 2000, Zhou et 
al. 2001, Huang et al. 2003, Kofuku et al. 2009). When comparing the amino acid 
sequences of human and mouse CXCR4, the second extracellular loop of CXCR4 
exhibits lower sequence identity (67%) than other extracellular regions (Nagasawa 
et al. 1996). Additionally, CF172 did not bind to mouse CXCR4 (Fig. 2-1b). 
Collectively, these results suggested that CF172 binds to the second extracellular 
loop of CXCR4, thereby exhibiting specific binding reactivity and inhibiting SDF1-
mediated signal transduction. 
By using CF172, the author demonstrated that SJCRH30 and RH30 cells were the 
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CXCR4-expressing rhabdomyosarcoma cells among the 5 different cell lines 
evaluated (Fig. 2-3). Both of these cell lines are histologically characterized as 
alveolar-type rhabdomyosarcoma, while the remaining 3 cell lines are characterized 
as the embryonal-type (Charrasse et al. 2004). The alveolar-type is known to be a 
more aggressive rhabdomyosarcoma than the embryonal-type (Newton et al. 1995, 
Leuschner and Harms 1999, Oberlin et al. 2008). The findings in this study that 
CXCR4 is preferentially expressed in the alveolar-type are consistent with previously 
published data indicating that high CXCR4 expression correlates with poor prognosis 
in rhabdomyosarcoma (Diomedi-Camassei et al. 2008). These findings also 
suggested the importance of CXCR4 in rhabdomyosarcoma. 
One of the most important findings was that CF172 inhibits the metastasis in two 
experimental rhabdomyosarcoma models (Fig. 2-7 and Fig. 2-9). Previous studies 
demonstrated that the SDF1 concentration in the peritoneum and lymph node is high 
(Muller et al. 2001, Yasumoto et al. 2006), suggesting that this high concentration of 
SDF1 enhances peritoneal and lymph node metastasis in rhabdomyosarcoma. The 
findings in this study that blocking the CXCR4/SDF1 axis by CF172 inhibited these 
metastases are consistent with this hypothesis and strongly support previously 
published conclusions that the CXCR4/SDF1 axis is important for tumor metastasis 
(Muller et al. 2001, Burger and Kipps 2006, Oda et al. 2007, Akashi et al. 2008, Joyce 
and Pollard 2009). These findings further suggest that the importance of 
CXCR4/SDF1 axis in tumor metastasis is also applicable to rhabdomyosarcoma. 
Compared to localized rhabdomyosarcoma, high mortality rates are still observed 
in patients with metastatic rhabdomyosarcoma, despite aggressive multimodality 
therapy (Koscielniak et al. 1992, Crist et al. 2001, Breneman et al. 2003, Stevens et 
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al. 2005, Oberlin et al. 2008, Malempati and Hawkins 2012). Therefore, new 
therapeutic agents for metastatic rhabdomyosarcoma are still necessary, and my 
finding that CF172 has potential as a therapeutic antibody for metastatic 
rhabdomyosarcoma is of significance. 
In conclusion, the results of the present study implicate CXCR4 signaling in the 
promotion of metastasis in rhabdomyosarcoma and CF172 was identified as a 
potential therapeutic antibody against metastatic rhabdomyosarcoma. 
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5.  Figures 
 
Fig. 2-1. Reaction specificity of CF172 against human CXCR4.  
The binding activity of CF172 to CHO cells stably expressing (a) human CXCR4, (b) 
mouse CXCR4 and (c) human CXCR2, was measured by flow cytometry. Background 
binding, measured with isotype control (solid area), is also shown. 
 
  
57 
 
 
 
  
58 
 
 
Fig. 2-2. Neutralization activity of CF172 against human CXCR4.  
The neutralization activity of CF172 for CXCR4 was measured using a cell-based assay. 
(a) Tango CXCR4-bla U2OS cells were incubated overnight at 37°C, followed by 5 h 
incubation in the presence of SDF1 (4 nM) and serially diluted CF172 (◆) or mIgG2b 
control (△). Samples were then incubated for 2 h with LiveBLAzer FRET B/G substrate. 
Signals for 4 or 0 nM of SDF1 with no antibody are indicated by the (+) or (-) dotted lines, 
respectively. (b) PathHunter CHO-K1 CXCR2 cells were incubated overnight at 37°C 
followed by 90 min incubation in the presence of CXCL8 (1.25 nM) and serially diluted 
CF172 (◆) or mIgG2b control (△). Samples were then incubated 1 h with PathHunter 
detection reagent. The signals for 1.25 or 0 nM of CXCL8 with no antibody are indicated 
by the (+) or (-) dotted lines, respectively. All points indicate the mean ± SD (n = 3).  
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Fig. 2-3. Analysis of CXCR4 expression in rhabdomyosarcoma cell lines.  
(a) CXCR4 membrane expression in rhabdomyosarcoma cell lines was analyzed by flow 
cytometry using CF172. Background binding, measured with isotype control (solid area), 
is also shown. (b) Expression of CXCR4 protein in 5 rhabdomyosarcoma cell lines was 
analyzed by western blot using anti-CXCR4 antibody. 
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Fig.2-4. Inhibitory activity of CF172 against biological activity of CXCR4 in 
SJCRH30.  
The ability of CF172 to inhibit biological activity of CXCR4 was measured using (a) 
SDF1/CXCR4-induced inhibitory activity of forskolin-stimulated cAMP production, and 
(b) SDF1/CXCR4-induced migration activity. (a) SJCRH30 cells were pretreated with 
serially diluted CF172 (■) or mIgG2b control (◯). Following this, cells were stimulated 
with 100 nM SDF1 and 25 μM forskolin. Cells were harvested 10 min later, and cAMP 
levels were assayed by ELISA. The signals for forskolin (25 μM) with 100 or 0 nM of 
SDF1, with no antibody, are indicated by the (+) or (-) dotted lines, respectively. (b) The 
xCELLigence system was used to monitor real-time cell migration. SJCRH30 cells with 
antibodies were seeded in the upper chamber of a CIM-Plate in the growth medium. The 
upper chamber was then placed on the lower chamber of the CIM-Plate containing 10 nM 
SDF1. Cell migration was monitored up to 7 h. All points indicate the mean ± SD (n = 3). 
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Fig. 2-5. Growth inhibition activity of CF172 against SJCRH30 cells.  
(a) SJCRH30 cells were incubated with or without 100 nM of SDF1 for 96 h. The 
number of living cells was then determined using Cell Counting Kit-8 solution. 
SJCRH30 cells were incubated with serially diluted CF172 (◆) and mIgG2b control (
◯) and (b) without 100 nM SDF1 or (c) with 100 nM SDF1 for 96 h. The number of 
living cells was then determined using Cell Counting Kit-8 solution. The cell number 
when 0 ng/mL antibody was added is indicated by the dotted line.   
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Fig. 2-6. Comparison of profile of SJCRH30 and SJCRH30-luc cells.  
(a) SJCRH30-luc was generated by transfection with a luciferase expression vector. 
Luciferase activity was confirmed by the Bright-Glo luciferase assay system (n = 3 for 
each cell line). (b) CXCR4 membrane expression in SJCRH30-luc was analyzed by 
flow cytometry using CF172. The background binding determined using the isotype 
control (solid area) is also shown. (c) The xCELLigence system was used to monitor 
real-time cell migration. SJCRH30-luc cells with antibodies were seeded in the growth 
medium in the upper chamber of a CIM-Plate. The upper chamber was then placed on 
the lower chamber of the CIM-Plate containing 10 nM SDF-1α. Cell migration was 
monitored over a period of up to 7 h. All points indicate the mean ± SD (n = 3). 
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Fig. 2-7. In vivo effect of CF172 against peritoneal metastasis of CXCR4-expressing 
rhabdomyosarcoma model.  
(a) The anti-peritoneal metastasis activity of CF172 against SJCRH30-luc cells was 
evaluated based on photon detection via bioimaging. SJCRH30-luc cells were 
intraperitoneally inoculated into nude mice. On the same day, CF172 (25 mg/kg) was 
intravenously injected in a single shot. After 5 days, metastasized tumor cells were 
measured by administration of luciferase substrate and detection of the photons. Data 
were individually plotted by % change from initial photon concentrations. Statistical tests 
were performed using Student’s t-test. (b) Photographs of all mice on day 5.  
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Fig. 2-8. Comparison of SDF1 concentration in ascites fluid of normal mice and 
SJCRH30-luc-xenografted mice.  
SDF1 concentration in ascites fluid of normal mice and SJCRH30-luc-xenografted 
mice was analyzed by Quantikine CXCL12/SDF-1 alpha ELISA kit (R&D systems). 
Assay was performed by n = 5. All values are expressed as the mean ± SD. 
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Fig. 2-9. In vivo effect of CF172 against tumor growth and lymph node metastasis of 
CXCR4-expressing rhabdomyosarcoma model.  
(a) Antitumor activity activity of CF172 against SJCRH30-luc cells was evaluated using 
subcutaneously implanted SJCRH30-luc cells. Once the tumors had reached a volume of 
approximately 100 mm3, mice were randomly assigned to two groups (n = 5) and twice-
weekly intravenous administration of CF172 (25 mg/kg) was performed for 14 days. The 
mean tumor volume is shown. Black triangle indicates administration day. (b) The anti-
metastasis activity of CF172 against lymph node metastasis of SJCRH30-luc was 
evaluated by detection of photons from lysed lymph nodes. Statistical tests were 
performed using the Wilcoxon test. 
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General Conclusion 
Tumor metastasis is an important determinant for tumor death and therapeutic modalities 
capable of inhibiting tumor metastasis should be beneficial for the treatment of many 
tumors. However, to date, no anti-metastatic drug is available.   
In this study, the author identified two anti-metastatic monoclonal antibodies, cVE199 
and CF172, which specifically target VEGF-D and CXCR4, respectively. Both antibodies 
presented anti-metastatic activities in animal models. 
In Chapter I, the author developed cVE199, a monoclonal antibody with specific 
reactivity to human VEGF-D (Fig. 1-1). The cVE199 molecule decreased the lymphatic 
metastasis through inhibition of tumor lymph vessel formation (Fig. 1-8). With regard to 
targeting tumor vessels, VEGF-A targeted therapies (e.g. anti-VEGF-A antibody: 
bevacizumab) that inhibit tumor blood vessel formation, showed a potent antitumor 
activity in preclinical models (Presta et al. 1997, Borgstrom et al. 1998, McMahon 2000, 
Mendel et al. 2000, Wood et al. 2000). Indeed anti-VEGF-A antibody, bevacizumab, has 
been clinically used for many tumor types (Hurwitz et al. 2004, Giantonio et al. 2007, 
Saltz et al. 2008, Leighl et al. 2010, Chang et al. 2011, Batchelor et al. 2014, Pujade-
Lauraine et al. 2014, von Minckwitz et al. 2014). However recent preclinical studies 
suggested that inhibition of VEGF-A signaling is accompanied by increased invasiveness 
and metastasis (Casanovas et al. 2005, Ebos et al. 2009, Paez-Ribes et al. 2009). The 
precise mechanisms of the exaggerated aggressiveness by VEGF-A targeted therapies are 
unknown, but a contributing factor could be hypoxia. Some reports showed that hypoxia 
promoted epithelial-mesenchymal transition (EMT) and EMT is believed to be a 
mechanism by which cancer cells become migratory and invasive (Sahlgren et al. 2008, 
Yang et al. 2008, Zhang et al. 2013). Other group reported that hypoxia upregulated the 
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transcription of c-Met, the tyrosine kinase receptor for hepatocyte growth factor (HGF) 
(Pennacchietti et al. 2003, Hara et al. 2006, Sennino et al. 2012). The c-Met/HGF signal 
transduction pathway plays a crucial role in controlling invasive growth of tumor cells. 
Thus, blood vessel inhibition is accompanied by increasing the number of malignant 
metastatic cells through hypoxia. Although cVE199 did not showed antitumor activity to 
primary tumors (Fig. 1-8a), the antibody significantly decreased lymphatic metastasis in 
an animal model through reduction of lymphangiogenesis. Therefore, targeting lymph 
vessels may be a better approach to generate anti-metastasis drugs. 
In Chapter II, the author developed CF172, a monoclonal antibody with specific 
reactivity to human CXCR4 (Fig. 2-1, 2-2). CF172 decreased metastasis by inhibiting 
tumor migration from the primary lesion without affecting tumor volume (Fig. 2-7, 2-9). 
Although there is no clinically used drug that target chemotaxis of tumors, matrix 
metalloproteinases (MMP) inhibitors present a similar mechanism of action. MMP 
degrade collagen and proteoglycans, the components of the extracellular matrix (ECM). 
ECM physically inhibits tumor chemotaxis. Thus, MMP-overexpressing-tumors present 
an increased chemotaxis activity through ECM degradation (Curran and Murray 1999, 
Johansson et al. 2000, Kerkela and Saarialho-Kere 2003). Many MMP inhibitors (e.g., 
Marimastat and BAY12-9566) have been tested in human clinical studies. However, no 
compound has been approved as an antitumor drug. Although many reasons for the lack 
of success of MMP inhibitors in clinical trials were considered, a contributing factor could 
be toxicity. The most frequent side-effect associated with MMP inhibitors in clinical trials 
was a musculoskeletal syndrome (MSS) that manifested as pain and immobility in the 
shoulder joints, arthralgias, contractures in the hands, and an overall reduced quality of 
life for patients. A current theory is that the side-effects are predominantly related to off-
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target metal chelation (Maquoi et al. 2004, Corbitt et al. 2007, Fingleton 2008, Li and Wu 
2010). Many efforts have been made to generate MMP inhibitors that have improved 
selectivity. However, there is no successful example in clinical trials. Therefore, MMPs 
seem to be tough targets to generate drug candidates. On the other hand, CF172 
specifically reacts to human CXCR4 and inhibits tumor metastasis in rhabdomyosarcoma 
models. Therefore, CXCR4 inhibition by CF172 may be a better approach to generate 
anti-metastasis drugs to target tumor chemotaxis.  
Both cVE199 and CF172 did not inhibit tumor growth. Thus, the combination of 
antitumor drugs (e.g., cytotoxic agents) with each antibody may be a better approach for 
cancer treatment. Alternatively, although cVE199 and CF172 showed anti-metastatic 
activities, both antibodies did not completely inhibit metastasis (Fig. 1-8, 2-7, 2-9). Both 
antibodies inhibited different steps of tumor metastasis. Thus, the combination of both 
antibodies seems better than monotherapy to completely inhibit metastasis, if the tumor 
expresses both VEGF-D and CXCR4. 
There is no molecular target agent for neuroblastoma and rhabdomyosarcoma treatment, 
which are the possible target indications of cVE199 and CF172 (Morgenstern et al. 2013, 
Hettmer et al. 2014). Therefore, my antibodies are of significance not only as novel anti-
metastasis agents, but also as novel molecular target agents for these tumor types. 
Furthermore, the identified cVE199 and CF172 antibodies are highly specific to VEGF-
D and CXCR4, respectively. Thus, these antibodies are useful not only for the 
development of drugs, but also as tools to understand the biological roles of each target 
protein, e.g., VEGF-D and CXCR4. 
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